Simulations Plus Insider Sold Shares Worth $670,150, According to a Recent SEC Filing
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Simulations Plus Supports FDA's Plan to Reduce Animal Testing With New Approach Methodologies
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Raises Target Price to $40
Simulations Plus Management to Meet With Stephens
Simulations Plus Price Target Raised to $40.00/Share From $32.00 by Keybanc
Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $40
Simulations Plus Analyst Ratings
KeyBanc Reaffirms Their Buy Rating on Simulations Plus (SLP)
What Does Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price Indicate?
Simulations Plus Up Over 30%, On Track for Largest Percent Increase Since November 2007 -- Data Talk
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
Gold Gains Over 2%; US Consumer Sentiment Dips In April
$SLP Stock Is up 16% Today. Here's What We See in Our Data.
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
U.S. stock movements | AI pharmaceutical development-related Concept stocks surge, Recursion Pharmaceuticals (RXRX.US) rises nearly 23%.
On Friday, stocks related to the concept of AI pharmaceutical development surged.
Market-Moving News for April 11th
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements